Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 13 points (-0.1%) at 18,099 as of Thursday, April 16, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,193 issues advancing vs. 1,740 declining with 211 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is down 0.1%. Top gainers within the industry include

Incyte

(

INCY

), up 1.6%, and

Illumina

(

ILMN

), up 0.8%. On the negative front, top decliners within the industry include

Teva Pharmaceutical Industries

(

TEVA

), down 2.2%,

Perrigo

(

PRGO

), down 1.6%,

Celgene

(

CELG

), down 1.5%,

Shire

(

SHPG

), down 1.1% and

Novo Nordisk A/S

(

NVO

), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Receptos

(

RCPT

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Receptos is up $8.19 (5.2%) to $166.51 on heavy volume. Thus far, 773,174 shares of Receptos exchanged hands as compared to its average daily volume of 737,500 shares. The stock has ranged in price between $162.00-$169.00 after having opened the day at $165.02 as compared to the previous trading day's close of $158.32.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Receptos has a market cap of $5.0 billion and is part of the health care sector. Shares are up 29.2% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate Receptos a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

Receptos

as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full

Receptos Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Amgen

(

AMGN

) is up $0.86 (0.5%) to $166.33 on average volume. Thus far, 1.5 million shares of Amgen exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $165.07-$167.24 after having opened the day at $166.40 as compared to the previous trading day's close of $165.47.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $123.2 billion and is part of the health care sector. Shares are up 3.9% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts who rate Amgen a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Amgen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

AbbVie

(

ABBV

) is up $0.58 (0.9%) to $62.61 on light volume. Thus far, 4.4 million shares of AbbVie exchanged hands as compared to its average daily volume of 12.6 million shares. The stock has ranged in price between $61.65-$62.87 after having opened the day at $61.80 as compared to the previous trading day's close of $62.03.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $98.3 billion and is part of the health care sector. Shares are down 5.2% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AbbVie

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and generally higher debt management risk. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null